A single-dose, open-label, two-treatment, two-period, two-sequence, two-way cross-over bioavailability & bioequivalence study to compare two formulation of Olmesartan 40 mg in healthy adults in fed state
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.